<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00039403</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02468</org_study_id>
    <secondary_id>DM01-553</secondary_id>
    <secondary_id>U01CA062461</secondary_id>
    <secondary_id>CDR0000069380</secondary_id>
    <nct_id>NCT00039403</nct_id>
  </id_info>
  <brief_title>UCN-01 and Gemcitabine in Treating Patients With Unresectable or Metastatic Pancreatic Cancer</brief_title>
  <official_title>A Phase I Study Of UCN-01 In Combination With Gemcitabine In Unresectable Or Metastatic Pancreatic Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase I trial to study the effectiveness of combining UCN-01 with gemcitabine in treating&#xD;
      patients who have unresectable or metastatic pancreatic cancer. Drugs used in chemotherapy&#xD;
      use different ways to stop tumor cells from dividing so they stop growing or die. UCN-01 may&#xD;
      help gemcitabine kill more cancer cells by making tumor cells more sensitive to the drug&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To determine the safety and toxicity profile of UCN-01 when given in combination with&#xD;
      gemcitabine to patients with unresectable or metastatic adenocarcinoma of the pancreas.&#xD;
&#xD;
      II. To characterize the pharmacokinetic profiles of gemcitabine and UCN-01 when given in&#xD;
      combination and to correlate various measurements of UCN-01 with intracellular&#xD;
      concentrations.&#xD;
&#xD;
      III. To determine recommended doses of UCN-01 and gemcitabine in combination to be used in a&#xD;
      planned subsequent phase II trial.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To record the frequency, extent, and duration of any tumor responses. II. To correlate&#xD;
      serum alpha-1 acid glycoprotein (AGP) levels with UCN-01 pharmacokinetics and toxicity.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation study.&#xD;
&#xD;
      Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3&#xD;
      hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or&#xD;
      unacceptable toxicity. Sequential dose escalation of UCN-01 is followed by sequential dose&#xD;
      escalation of gemcitabine.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the&#xD;
      maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose&#xD;
      preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
      Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2002</start_date>
  <primary_completion_date type="Actual">May 2006</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of toxicity</measure>
    <time_frame>Up to 4 years</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profiles</measure>
    <time_frame>Weeks 1-6 for UCN-01 and weeks 1 and 4 for intracellular gemcitabine</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Recommended phase II doses</measure>
    <time_frame>3 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Frequency, extent, and duration of any tumor responses</measure>
    <time_frame>Up to 4 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Adenocarcinoma of the Pancreas</condition>
  <condition>Recurrent Pancreatic Cancer</condition>
  <condition>Stage II Pancreatic Cancer</condition>
  <condition>Stage III Pancreatic Cancer</condition>
  <condition>Stage IV Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (UCN-01, gemcitabine hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive gemcitabine IV over 1-2 hours on days 1 and 8 followed by UCN-01 IV over 3 hours on day 1. Courses repeat every 3 weeks in the absence of disease progression or unacceptable toxicity.&#xD;
Sequential dose escalation of UCN-01 is followed by sequential dose escalation of gemcitabine. Cohorts of 3-6 patients receive escalating doses of UCN-01 and then gemcitabine until the maximum tolerated dose (MTD) of the combination is determined. The MTD is defined as the dose preceding that at which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, at least 6 patients are treated at the recommended phase II dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>7-hydroxystaurosporine</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (UCN-01, gemcitabine hydrochloride)</arm_group_label>
    <other_name>UCN-01</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (UCN-01, gemcitabine hydrochloride)</arm_group_label>
    <other_name>dFdC</other_name>
    <other_name>difluorodeoxycytidine hydrochloride</other_name>
    <other_name>gemcitabine</other_name>
    <other_name>Gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (UCN-01, gemcitabine hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (UCN-01, gemcitabine hydrochloride)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically confirmed unresectable or metastatic adenocarcinoma of&#xD;
             the pancreas&#xD;
&#xD;
          -  Unidimensionally measurable disease&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
               -  At least 10 mm by spiral CT scan&#xD;
&#xD;
               -  Tumor lesions in a previously irradiated area are not considered measurable&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
               -  Patients with signs or symptoms of CNS metastasis at any time during screening&#xD;
                  must have a negative CT scan or MRI of the brain&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  Performance status - Karnofsky 60-100%&#xD;
&#xD;
          -  More than 3 months&#xD;
&#xD;
          -  WBC at least 3,000/mm^3&#xD;
&#xD;
          -  Absolute neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count greater than 100,000/mm^3&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST no greater than 2.5 times upper limit of normal&#xD;
&#xD;
          -  Creatinine normal&#xD;
&#xD;
          -  Creatinine clearance at least 60 mL/min&#xD;
&#xD;
          -  No prior coronary artery disease&#xD;
&#xD;
          -  No symptomatic cardiac dysfunction&#xD;
&#xD;
          -  No prior myocardial infarction&#xD;
&#xD;
          -  No active angina (even if controlled by medication)&#xD;
&#xD;
          -  No positive stress test&#xD;
&#xD;
          -  No uncontrolled arrhythmia&#xD;
&#xD;
          -  Left ventricular ejection fraction at least 45%&#xD;
&#xD;
          -  Patients with symptoms suggestive of coronary artery disease or arrhythmia must have&#xD;
             no evidence of cardiac pathology&#xD;
&#xD;
          -  No symptomatic pulmonary dysfunction&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3 months after study&#xD;
             participation&#xD;
&#xD;
          -  No prior allergic reactions attributed to compounds of similar chemical or biological&#xD;
             composition to UCN-01 or other study agents&#xD;
&#xD;
          -  No insulin-dependent diabetes mellitus&#xD;
&#xD;
          -  No other concurrent uncontrolled illness&#xD;
&#xD;
          -  No ongoing or active infections&#xD;
&#xD;
          -  No concurrent psychiatric illness&#xD;
&#xD;
          -  No other active malignancy&#xD;
&#xD;
          -  No other solid tumor within the past 5 years except neoplasia in situ or&#xD;
             nonmelanomatous skin cancer&#xD;
&#xD;
          -  No social situations that would preclude study compliance&#xD;
&#xD;
          -  No concurrent over-the-counter biologics&#xD;
&#xD;
          -  No concurrent growth factors during the first study course&#xD;
&#xD;
          -  At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin) and&#xD;
             recovered&#xD;
&#xD;
          -  No more than 2 prior chemotherapy regimens (e.g., gemcitabine and/or experimental&#xD;
             agents) alone or in combination with radiotherapy as neoadjuvant or adjuvant therapy&#xD;
             for resectable, unresectable, or metastatic disease&#xD;
&#xD;
          -  See Chemotherapy&#xD;
&#xD;
          -  At least 6 weeks since prior radiotherapy and recovered&#xD;
&#xD;
          -  Prior radiotherapy directed only at the primary tumor bed allowed&#xD;
&#xD;
          -  No prior radiotherapy to the mediastinum, pelvis, lower spine, or more than 20% of&#xD;
             bone marrow&#xD;
&#xD;
          -  At least 4 weeks since prior major surgery&#xD;
&#xD;
          -  At least 4 weeks since prior investigational agents&#xD;
&#xD;
          -  Concurrent enrollment in non-therapy trials (e.g., quality of life) allowed&#xD;
&#xD;
          -  No concurrent herbal remedies&#xD;
&#xD;
          -  No concurrent treatment for another active malignancy&#xD;
&#xD;
          -  No concurrent warfarin for anticoagulation&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
&#xD;
          -  No other concurrent investigational or commercial anticancer agents or therapies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Linus Ho</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>June 6, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>7-hydroxystaurosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

